Pharmaceuticals, Biotechnology and Life Sciences
Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.
Urges Shareholders to Vote “FOR” the Proposed Transaction on the WHITE Proxy Card NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY)…
Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
In addition to today’s news about Yervoy in combination with Opdivo , Bristol-Myers Squibb said today that the European Commission (EC) has…
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
Bristol-Myers Squibb has completed its previously announced acquisition of IFM Therapeutics, the company said on Thursday.
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on three Opdivo-based combination clinical studies in…
Bristol-Myers Squibb announced results from the CheckMate -214 trial on Tuesday, investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma.
Bristol-Myers Squibb on Wednesday said it would present 23 abstracts related to Orencia (abatacept), including new data on the role of biomarkers and MRI in RA patient identification and treatment, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, Spain.
Bristol-Myers Squibb and CytomX Therapeutics, a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, have expanded their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform.